Volpara Health Technologies (ASX:VHT) - CEO, Dr Ralph Highnam
CEO, Dr Ralph Highnam
Source: Volpara
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Volpara Health Technologies (VHT) has been granted another patent from the European patent office covering the company’s method of image quantification
  • The patent covers the company’s improved breast cancer screening analysis and is effective across 25 European countries
  • Research suggests patients could benefit from a baseline mammogram to assess their breast cancer risk before the standard screening age of 40
  • Volpara Chief Financial Officer Craig Hadfield says the company’s patent portfolio forms part of its broader sales and growth strategy
  • Volpara Health Technologies shares closed today’s session down 3.33 per cent to trade at $1.16

Volpara Health Technologies (VHT) has been granted another patent from the European patent office covering the company’s method of image quantification.

The latest patent, which is effective across 25 European countries, takes the company’s total patent portfolio to 98.

Specifically, Volpara said the patent covers its improved analysis of low-dose images, enabling a more accurate assessment of a woman’s breast composition at an early age and calculating her baseline risk of breast cancer.

Volpara Chief Financial Officer Craig Hadfield commented on the patent win.

“These patents work together with Volpara’s other international intellectual property rights to facilitate the sales and growth strategy for Volpara’s product line,” he said.

The company said research studies suggest patients should receive a baseline mammogram to assess their breast cancer risk before they reach the standard screening age of 40.

A patient considered high risk may then be directed to begin annual screenings earlier than usual.

Volpara is looking to provide high-sensitivity, low-dose cancer screening for women between the ages of 25 and 30 without the radiation effects typically associated with standard cancer screenings.

Volpara Health Technologies shares closed today’s session down 3.33 per cent to trade at $1.16.

VHT by the numbers
More From The Market Herald
Argenica Therapeutics (ASX:AGN) - CEO, Dr Liz Dallimore

" Argenica Therapeutics (ASX:AGN) determines safe starting dose level for ARG-007

Argenica Therapeutics (ASX:AGN) determines safe starting dose level from toxicology and genotoxicity studies
Arovella Therapeutics (ASX:ALA) - CEO and Managing Director, Dr Michael Baker

" Arovella Therapeutics (ASX:ALA) to raise $6m for cell therapies

Arovella Therapeutics (ASX:ALA) has received firm commitments from institutional and sophisticated investors for a $4.57 million…

" Radiopharm Theranostics (ASX:RAD) acquires IP ownership of Radiopharmaceutical Nanobodies

Radiopharm Theranostics (ASX:RAD) acquires full intellectual property (IP) ownership to three assets from NanoMab Technology.
Nuheara (ASX:NUH) - CEO, Justin Miller

" Nuheara (ASX:NUH) completes $1.06m SPP

Hearing technology company Nuheara (ASX:NUH) has completed its share purchase plan (SPP) with applications totalling $1,067,200.